TimesSquare Capital Management LLC Takes $15.90 Million Position in Tarsus Pharmaceuticals, Inc. $TARS

TimesSquare Capital Management LLC bought a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 267,505 shares of the company’s stock, valued at approximately $15,898,000.

A number of other institutional investors have also bought and sold shares of TARS. Osaic Holdings Inc. lifted its position in shares of Tarsus Pharmaceuticals by 779.1% in the second quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock valued at $113,000 after acquiring an additional 2,462 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Tarsus Pharmaceuticals by 220.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company’s stock worth $164,000 after purchasing an additional 2,782 shares in the last quarter. West Wealth Group LLC bought a new position in Tarsus Pharmaceuticals in the 3rd quarter worth approximately $202,000. Valeo Financial Advisors LLC purchased a new stake in Tarsus Pharmaceuticals during the 3rd quarter valued at approximately $209,000. Finally, Allianz Asset Management GmbH bought a new stake in shares of Tarsus Pharmaceuticals during the second quarter valued at approximately $227,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Trading Down 3.9%

TARS opened at $60.78 on Monday. The stock has a 50-day moving average of $74.28 and a 200 day moving average of $67.20. The company has a current ratio of 4.29, a quick ratio of 4.25 and a debt-to-equity ratio of 0.22. Tarsus Pharmaceuticals, Inc. has a 12 month low of $38.51 and a 12 month high of $85.25. The firm has a market cap of $2.58 billion, a P/E ratio of -30.09, a P/E/G ratio of 0.88 and a beta of 0.57.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, insider Dianne C. Whitfield sold 7,397 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $80.10, for a total value of $592,499.70. Following the completion of the sale, the insider owned 38,958 shares in the company, valued at approximately $3,120,535.80. This trade represents a 15.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bobak R. Azamian sold 6,000 shares of the company’s stock in a transaction dated Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total transaction of $495,060.00. Following the transaction, the chief executive officer owned 857,991 shares in the company, valued at $70,792,837.41. The trade was a 0.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 8.97% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on TARS. Wall Street Zen upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Guggenheim increased their price objective on shares of Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Mizuho began coverage on Tarsus Pharmaceuticals in a report on Thursday, November 20th. They issued an “outperform” rating and a $100.00 target price on the stock. Barclays initiated coverage on Tarsus Pharmaceuticals in a research note on Monday, December 8th. They set an “overweight” rating and a $100.00 price target for the company. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $68.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $82.29.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.